TED 2015_15 CNCD vs Francisco Ruiz Gavilán

26 Nov 2015

In July 2015 the National Doping Control Commission of Chile (CNCD) has reported an anti-doping rule violation against the rower Francisco Ruiz Gavilán after his sample tested positive for the prohibited substance Furosemide.

After notification a provisional suspension was ordered and the Athlete was heard for the Disciplinary Panel of the Tribunal de Expertos en Dopaje (TED).

The Athlete admitted the violation and denied the intentional use of the substance. He explained that the substance was used to stay within the intended weight class.

The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.

Therefore the TED Disciplinary Panel decides on 26 November 2015 to impose 2 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 2 July 2015.

TED 2015_12 CNCD vs Rodígo Muñoz Stantibáñez

26 Nov 2015

In July 2015 the National Doping Control Commission of Chile (CNCD) has reported an anti-doping rule violation against the rower Rodígo Muñoz Stantibáñez after his sample tested positive for the prohibited substances Canrenone and Furosemide.

After notification a provisional suspension was ordered and the Athlete was heard for the Disciplinary Panel of the Tribunal de Expertos en Dopaje (TED).

The Athlete admitted the violation and denied the intentional use of the substance. He explained that the substance was used to stay within the intended weight class.

The Panel finds that the presence of a prohibited substances has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.

Therefore the TED Disciplinary Panel decides on 26 November 2015 to impose 2 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 2 July 2015.

TED 2015_11 CNCD vs Nelson Martínez Hodde

26 Nov 2015

In July 2015 the National Doping Control Commission of Chile (CNCD) has reported an anti-doping rule violation against the rower Nelson Martínez Hodde after his sample tested positive for the prohibited substance Furosemide.

After notification a provisional suspension was ordered and the Athlete was heard for the Disciplinary Panel of the Tribunal de Expertos en Dopaje (TED).

The Athlete admitted the violation and denied the intentional use of the substance. He explained that the substance was used to stay within the intended weight class.

The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.

Therefore the TED Disciplinary Panel decides on 26 November 2015 to impose 2 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 2 July 2015.

TED 2015_08 CNCD vs Francisco Moreno Cornejo

22 Sep 2015

In April 2015 the National Doping Control Commission of Chile (CNCD) has reported an anti-doping rule violation against the cyclist Francisco Moreno Cornejo after his A and B samples tested positive for the prohibited substance Hydrochlorothiazide.

After notification a provisional suspension was ordered and the Athlete was heard for the Disciplinary Panel of the Tribunal de Expertos en Dopaje (TED).

The Panel finds that the presence of a prohibited substance has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.

The Panel considers that the Athlete explained how the substance had entered his system without grounds for a reduced sanction.

Therefore the TED Disciplinary Panel decides on 22 September 2015 to impose 2 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 1 April 2015.

TED 2015_07 CNCD vs Pablo Gómez Valenzuela

22 Sep 2015

In April 2015 the National Doping Control Commission of Chile (CNCD) has reported an anti-doping rule violation against the cyclist Pablo Gómez Valenzuela after his sample tested positive for the prohibited substances 19-norandrosterone 19-noretiocholanolone (Nandrolone) and Mesterolone.

After notification a provisional suspension was ordered and the Athlete failed to attend the hearing of the Disciplinary Panel of the Tribunal de Expertos en Dopaje (TED).

The Panel finds that the presence of prohibited substancse has been established in the Athlete's sample and accordingly that he committed an anti-doping rule violation.

Therefore the TED Disciplinary Panel decides on 22 September 2015 to impose 4 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 1 April 2015.

UKAD 2021 RFU vs Christopher Mayor

22 Jun 2022

In September 2019, United Kingdom Anti-Doping (UKAD) was informed by Law Enforcement that the rugby player Christopher Mayor was involved in the use and traffic of 72iu Lilly Pen, i.e. Human Growth Hormone (hGH).

After notification in November 2019 a provisional suspension was ordered and the Athlete was heard by UKAD. The Athlete confirmed that in the captured Facebook messages he had been interested in the purchase of hGH. Thereupon the case was referred to the National Anti-Doping Panel (NADP).

The Athlete denied that he ever had possessed, used or trafficked any prohibited substance. He only acknowledged that in the Facebook messages he had shown his interest in the purchase of hGH to assist his father suffering from a knee injury. He was aware that hGH is a prohibited substance whereas he alleged that this attempt occurred in a context unrelated to sport enhancement.

The RFU acknowledged that there was no evidence that the Athlete indeed had purchased hGH. Yet, the Athlete's Facebook messages addressed to the other person showed that he attempted to purchase hGH. He asked for a specific product 72iu Lilly Pen that won't easy surface in a brief internet research. Further he had a longstanding relationship with the other person and he had just started pre-season training with a new club while he had to improve his level of fitness.

In view of the Facebook messages the Panel does not accept that the Athlete indeed had purchased 72iu Lilly Pen nor that the trafficking of the substance had been established. The Panel however concludes that the Athlete took substantial steps in his attempts to use and traffick the prohibited substance.

Therefore the National Anti-Doping Panel deems on 20 May 2022 that the Athlete had committed anti-doping rule violations in his attempt to use and traffick a prohibited substance.

Following the written submissions of the parties on sanction the National Anti-Doping Panel decides on 22 June 2022 to impose a 4 year period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 8 November 2021.

Minderjarigen en het antidopingbeleid – Deel 2

1 Jul 2022

Minderjarigen en het antidopingbeleid – deel 2 / H. Ram

  • Tijdschrift voor Sport & Recht (2022) 1, p. 1-10



In dit tweede deel van dit artikel wordt de jurisprudentie inzake door minderjarige sporters begane dopingovertredingen besproken. Daarbij wordt eerst onderzocht hoe de regels in de Wereld Anti-Doping Code (WADC) die specifiek betrekking heeft op minderjarige sporters, inclusief de specifieke regels die het verloop van dopingcontroles bij minderjarige sporters beheersen, worden toegepast. Vervolgens wordt onderzocht hoe minderjarigheid wordt meegewogen en welke factoren daarbij een rol spelen, in het bijzonder bij het bepalen van de strafmaat. Het artikel sluit af met enige conclusies en een jurisprudentieoverzicht.

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial

7 Mar 2012

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production : a randomized controlled trial / Shalender Bhasin, Thomas G. Travison, Thomas W Storer, Kishore Lakshman, Manas Kaushik, Norman A. Mazer, Ahn-Hoa Ngyuen, Maithili N. Davda, Hernan Jara, Adam Aakil, Stephan Anderson, Philip E. Knapp, Samson Hanka, Nurahmed Mohammed, Pierre Daou, Renee Miciek, Jagadish Ulloor, Anqi Zhang, Brad Brooks, Katie Orwoll, Leife Hede-Brierley, Richard Eder, Ayan Elmi, Geeta Bhasin, Lauren Collins, Ravinder Singh, Shehzad Basaria

  • Journal of the American Medical Association 307 (2012) 9 (7 March), p. 931-939
  • PMID: 22396515
  • PMCID: PMC6035750
  • DOI: 10.1001/jama.2012.227


Abstract

Context: Steroid 5α-reductase inhibitors are used to treat benign prostatic hyperplasia and androgenic alopecia, but the role of 5α-dihydrotestosterone (DHT) in mediating testosterone's effects on muscle, sexual function, erythropoiesis, and other androgen-dependent processes remains poorly understood.

Objective: To determine whether testosterone's effects on muscle mass, strength, sexual function, hematocrit level, prostate volume, sebum production, and lipid levels are attenuated when its conversion to DHT is blocked by dutasteride (an inhibitor of 5α-reductase type 1 and 2).

Design, setting, and patients: The 5α-Reductase Trial was a randomized controlled trial of healthy men aged 18 to 50 years comparing placebo plus testosterone enthanate with dutasteride plus testosterone enanthate from May 2005 through June 2010.

Interventions: Eight treatment groups received 50, 125, 300, or 600 mg/wk of testosterone enanthate for 20 weeks plus placebo (4 groups) or 2.5 mg/d of dutasteride (4 groups).

Main outcome measures: The primary outcome was change in fat-free mass; secondary outcomes: changes in fat mass, muscle strength, sexual function, prostate volume, sebum production, and hematocrit and lipid levels.

Results: A total of 139 men were randomized; 102 completed the 20-week intervention. Men assigned to dutasteride were similar at baseline to those assigned to placebo. The mean fat-free mass gained by the dutasteride groups was 0.6 kg (95% CI, -0.1 to 1.2 kg) when receiving 50 mg/wk of testosterone enanthate, 2.6 kg (95% CI, 0.9 to 4.3 kg) for 125 mg/wk, 5.8 kg (95% CI, 4.8 to 6.9 kg) for 300 mg/wk, and 7.1 kg (95% CI, 6.0 to 8.2 kg) for 600 mg/wk. The mean fat-free mass gained by the placebo groups was 0.8 kg (95% CI, -0.1 to 1.7 kg) when receiving 50 mg/wk of testosterone enanthate, 3.5 kg (95% CI, 2.1 to 4.8 kg) for 125 mg/wk, 5.7 kg (95% CI, 4.8 to 6.5 kg) for 300 mg/wk, and 8.1 kg (95% CI, 6.7 to 9.5 kg) for 600 mg/wk. The dose-adjusted differences between the dutasteride and placebo groups for fat-free mass were not significant (P = .18). Changes in fat mass, muscle strength, sexual function, prostate volume, sebum production, and hematocrit and lipid levels did not differ between groups.

Conclusion: Changes in fat-free mass in response to graded testosterone doses did not differ in men in whom DHT was suppressed by dutasteride from those treated with placebo, indicating that conversion of testosterone to DHT is not essential for mediating its anabolic effects on muscle.

Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle

1 Feb 2005

Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle / Shalender Bhasin, Linda Woodhouse, Richard Casaburi, Atam B. Singh, Ricky Phong Mac, Martin Lee, Kevin E. Yarasheski, Indrani Sinha-Hikim, Connie Dzekov, Jeanne Dzekov, Lynne Magliano, Thomas W. Storer

  • Journal of Clinical Endocrinology & Metabolism 90 (2005) 2 (1 February), p. 678-688
  • PMID: 15562020
  • DOI: 10.1210/jc.2004-1184


Abstract

Although testosterone levels and muscle mass decline with age, many older men have serum testosterone level in the normal range, leading to speculation about whether older men are less sensitive to testosterone. We determined the responsiveness of androgen-dependent outcomes to graded testosterone doses in older men and compared it to that in young men. The participants in this randomized, double-blind trial were 60 ambulatory, healthy, older men, 60-75 yr of age, who had normal serum testosterone levels. Their responses to graded doses of testosterone were compared with previous data in 61 men, 19-35 yr old. The participants received a long-acting GnRH agonist to suppress endogenous testosterone production and 25, 50, 125, 300, or 600 mg testosterone enanthate weekly for 20 wk. Fat-free mass, fat mass, muscle strength, sexual function, mood, visuospatial cognition, hormone levels, and safety measures were evaluated before, during, and after treatment. Of 60 older men who were randomized, 52 completed the study. After adjusting for testosterone dose, changes in serum total testosterone (change, -6.8, -1.9, +16.1, +49.5, and +101.9 nmol/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) and hemoglobin (change, -3.6, +9.9, +20.9, +12.6, and +29.4 g/liter at 25, 50, 125, 300, and 600 mg/wk, respectively) levels were dose-related in older men and significantly greater in older men than young men (each P < 0.0001). The changes in FFM (-0.3, +1.7, +4.2, +5.6, and +7.3 kg, respectively, in five ascending dose groups) and muscle strength in older men were correlated with testosterone dose and concentrations and were not significantly different in young and older men. Changes in fat mass correlated inversely with testosterone dose (r = -0.54; P < 0.001) and were significantly different in young vs. older men (P < 0.0001); young men receiving 25- and 50-mg doses gained more fat mass than older men (P < 0.0001). Mood and visuospatial cognition did not change significantly in either group. Frequency of hematocrit greater than 54%, leg edema, and prostate events were numerically higher in older men than in young men. Older men are as responsive as young men to testosterone's anabolic effects; however, older men have lower testosterone clearance rates, higher increments in hemoglobin, and a higher frequency of adverse effects. Although substantial gains in muscle mass and strength can be realized in older men with supraphysiological testosterone doses, these high doses are associated with a high frequency of adverse effects. The best trade-off was achieved with a testosterone dose (125 mg) that was associated with high normal testosterone levels, low frequency of adverse events, and significant gains in fat-free mass and muscle strength.

iNADO Update #2022-07

11 Jul 2022

iNADO Update (2022) 07 (11 July)
Institute of National Anti-Doping Organisations (iNADO)


Contents:

iNADO Community

  • iNADO 2022 Workshop
  • National Integrity Framework - Sport Integrity Australia
  • Partnership for Clean Competition Podcast

Bulletin Board

  • iNADO Member-Only Webinar: AFLD’s Compliance with the World Anti-Doping Code: Challenges and Achievements
  • iNADO Welcomes Adoption of a Declaration of 'Guiding Principles for the Future of Anti-Doping'
  • Uneven Accountability in Anti-Doping: The Role of Socio-Economic and Political Factors Unobserved in the Current System
  • Jeremy Roubin, Secretary General of AFLD

Science

  • Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti-doping application

Practical Development in Anti-Doping

  • Swiss Sport Integrity creates 'Parents' Forum'

Feature of the Month

  • WADA Athlete Biological Passport (ABP) Symposium

iNADO Partners & Sponsors

  • New at the Anti-Doping Knowledge Center
Category
  • Legal Source
  • Education
  • Science
  • Statistics
  • History
Country & language
  • Country
  • Language
Other filters
  • ADRV
  • Legal Terms
  • Sport/IFs
  • Other organisations
  • Laboratories
  • Analytical aspects
  • Doping classes
  • Substances
  • Medical terms
  • Various
  • Version
  • Document category
  • Document type
Publication period
Origin